<bill session="118" type="h" number="6227" updated="2024-07-23T08:05:23Z">
  <state datetime="2023-11-03">REFERRED</state>
  <status>
    <introduced datetime="2023-11-03"/>
  </status>
  <introduced datetime="2023-11-03"/>
  <titles>
    <title type="display">Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023</title>
    <title type="short" as="introduced">Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.</title>
  </titles>
  <sponsor bioguide_id="S001183"/>
  <cosponsors>
    <cosponsor bioguide_id="A000377" joined="2023-11-03"/>
    <cosponsor bioguide_id="B001306" joined="2024-02-23"/>
    <cosponsor bioguide_id="B000740" joined="2024-01-11"/>
    <cosponsor bioguide_id="B001275" joined="2024-02-23"/>
    <cosponsor bioguide_id="B001248" joined="2023-11-03"/>
    <cosponsor bioguide_id="C001134" joined="2023-11-03"/>
    <cosponsor bioguide_id="C001133" joined="2023-11-03"/>
    <cosponsor bioguide_id="C001059" joined="2023-11-03"/>
    <cosponsor bioguide_id="C001120" joined="2024-03-13"/>
    <cosponsor bioguide_id="D000594" joined="2023-11-03"/>
    <cosponsor bioguide_id="F000468" joined="2023-12-19"/>
    <cosponsor bioguide_id="F000480" joined="2024-07-22"/>
    <cosponsor bioguide_id="G000574" joined="2023-11-03"/>
    <cosponsor bioguide_id="G000551" joined="2023-11-03"/>
    <cosponsor bioguide_id="H001086" joined="2024-03-13"/>
    <cosponsor bioguide_id="J000302" joined="2023-12-13"/>
    <cosponsor bioguide_id="L000578" joined="2023-11-29"/>
    <cosponsor bioguide_id="L000590" joined="2023-12-19"/>
    <cosponsor bioguide_id="L000273" joined="2024-01-11"/>
    <cosponsor bioguide_id="L000589" joined="2023-11-08"/>
    <cosponsor bioguide_id="L000593" joined="2023-11-03"/>
    <cosponsor bioguide_id="M001165" joined="2023-11-03"/>
    <cosponsor bioguide_id="M001215" joined="2023-12-19"/>
    <cosponsor bioguide_id="M001213" joined="2023-12-19"/>
    <cosponsor bioguide_id="M001225" joined="2023-12-13"/>
    <cosponsor bioguide_id="O000019" joined="2023-12-04"/>
    <cosponsor bioguide_id="P000608" joined="2023-12-05"/>
    <cosponsor bioguide_id="P000620" joined="2023-11-29"/>
    <cosponsor bioguide_id="P000048" joined="2024-02-05"/>
    <cosponsor bioguide_id="S001226" joined="2024-02-23"/>
    <cosponsor bioguide_id="S001224" joined="2023-11-03"/>
    <cosponsor bioguide_id="S001218" joined="2023-11-29"/>
    <cosponsor bioguide_id="S001135" joined="2023-11-03"/>
    <cosponsor bioguide_id="S001193" joined="2023-11-29"/>
    <cosponsor bioguide_id="V000129" joined="2023-11-03"/>
  </cosponsors>
  <actions>
    <action datetime="2023-11-03">
      <text>Introduced in House</text>
    </action>
    <action datetime="2023-11-03" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2023-11-10">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="118" type="s" number="3220" relation="unknown"/>
    <bill session="118" type="h" number="6731" relation="unknown"/>
    <bill session="118" type="s" number="3464" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Cardiovascular and respiratory health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Health promotion and preventive care"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2024-01-24T21:21:31Z" status="Introduced in House">Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.</summary>
</bill>
